

Scientific Program

Day 1: December 17 (Friday) 2021

Room 1

7:50-8:00 Opening Ceremony

Dr. Mitsuhiro Moriyama (President of APASL Oncology 2021)

8:00-9:00 Morning Seminar (1) (Sponsored by Chugai Pharmaceutical Co., Ltd.)

Chair: Dr. Masao Omata (Japan)

Toward Further Advancement of Molecular Targeted Therapy Using Liquid Biopsy in HCC

Dr. Sadakatsu Ikeda (Japan)

9:10-10:40 Session 1: Molecular Mechanism of HCC (1)

Chairs: Dr. Ranjit Ray (USA)/Dr. Naoshi Nishida (Japan)

9:10-9:25 1-1 **Risk Assessment of Hepatocellular Carcinoma Development-clinical and Molecular Perspective**

Dr. Ryota Masuzaki (Japan)

9:25-9:40 1-2 **Role of FGF19/FGFR4 Signaling and Potential of Serum FGF19 as a Biomarker in Hepatocellular Carcinoma.**

Dr. Tetsuhiro Chiba (Japan)

9:40-9:55 1-3 **Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression**

Dr. Yutaka Midorikawa (Japan)

9:55-10:10 1-4 **Linking lncRNA Linc-Pint with Liver Disease**

Dr. Ratna B. Ray (USA)

10:10-10:25 1-5 **Genetic and Epigenetic Basis of Pediatric Liver Tumors**

Dr. Hiroyuki Aburatani (Japan)

10:25-10:40 Discussion Time

10:50-12:20 Session 2: Intermediate-stage HCC (TKI, Lenvatinib) (1)

Chairs: Dr. Masafumi Ikeda (Japan)/Dr. Tawesak Tawandee (Thailand)

10:50-11:05 2-1 **Analysis for Transition of Molecular Target Agent Therapy and Prognosis in Advanced Hepatocellular Carcinoma**

Dr. Kazufumi Kobayashi (Japan)

11:05-11:20 2-2 **HCC Following Hepatitis C Virus Eradication**

Dr. Massimo Colombo (Italy)

11:20-11:35 2-3 **Integrating Systemic Therapy into Multidisciplinary Treatment of HCC**

Dr. Ann-Lii Cheng (Taiwan)

- 11:35-11:50 **2-4 Systemic Treatment Including Lenvatinib in Patients with BCLC-B Stage Hepatocellular Carcinoma**
Dr. Atsushi Hiraoka (Japan)
- 11:50-12:05 **2-5 Identification of Tumor Factors of Hepatocellular Carcinoma that Decrease the Efficacy of Immune Checkpoint Inhibitors**
Dr. Masao Honda (Japan)
- 12:05-12:20 Discussion Time

12:30-13:30 Luncheon Seminar (1) (Sponsored by Chugai Pharmaceutical Co., Ltd.)

Chair: Dr. Masatoshi Kudo (Japan)

Novel Cancer Immunotherapy for Hepatocellular Carcinoma: Evidence and Management

Dr. Masafumi Ikeda (Japan)

Exploring Next-Gen Systemic Therapy for HCC: What Have We Learned?

Dr. Ann-Lii Cheng (Taiwan)

13:40-14:20 President Lecture (Sponsored by Towa Pharmaceutical Co., Ltd.)

Chair: Dr. Masao Omata (Japan)

Considering the Occurrence of Liver Cancer from Chronic Hepatitis C / Cirrhosis in Japan

Dr. Mitsuhiko Moriyama (President of APASL Oncology 2021)

14:30-16:00 Session 3: Intermediate-stage HCC (2)

Chairs: Dr. George Lau (China)/Dr. Atsumasa Komori (Japan)/Dr. Tsutomu Masaki (Japan)

- 14:30-14:45 **3-1 Treatment Strategy for Intermediate Stage HCC**
Dr. Masafumi Ikeda (Japan)
- 14:45-15:00 **3-2 Paradigm Shift with Drug Therapy in the Treatment of Intermediate-Stage Hepatocellular Carcinoma**
Dr. Tatsuya Yamashita (Japan)
- 15:00-15:15 **3-3 Treatment Strategy for Intermediate Stage HCC with Consideration of Maintaining Liver Function**
Dr. Naoya Kato (Japan)
- 15:15-15:30 **3-4 Systemic Therapy in the Intermediate Stage HCC: Current Evidence and Future Perspective**
Dr. Changhoon Yoo (Korea)
- 15:30-15:45 **3-5 Treatment Strategy of Intermediate-stage HCC: ABC Conversion Therapy**
Dr. Masatoshi Kudo (Japan)
- 15:45-16:00 Discussion Time

16:10-17:40 Session 4: Pathology of HCC

Chairs: Dr. Shinichi Aishima (Japan)/Dr. Kenichi Harada (Japan)/Dr. Michiie Sakamoto (Japan)

- 16:10-16:25 **4-1 Tumour Heterogeneity of HCC and Its Clinical Relevance**
Dr. Mina Komuta (Japan)

16:25-16:40	4-2 Pathological Features of Tumor Microenvironment of HCC Dr. Michiie Sakamoto (Japan)
16:40-16:55	4-3 Genomic Structures and Carcinogenesis of HBV Integrations in Liver Cancer Dr. Hidewaki Nakagawa (Japan)
16:55-17:10	4-4 Update in HCC Pathology Dr. Young Nyun Park (Korea)
17:10-17:25	4-5 Morphological Subtypes of Hepatocellular Carcinoma Dr. Shinichi Aishima (Japan)
17:25-17:40	Discussion Time

17:50-19:20 Session 5: Oncoimmunotherapy for HCC

Chairs: Dr. Shiv K. Sarin (India)/Dr. Masao Omata (Japan)

17:50-18:05	5-1 Mechanism of Resistance to Immunotherapy for Hepatocellular Carcinoma Dr. Kazuomi Ueshima (Japan)
18:05-18:20	5-2 Dramatic Transformation of Treatments in Patients with Advanced Hepatocellular Carcinoma Dr. Sadahisa Ogasawara (Japan)
18:20-18:35	5-3 Oncoimmunotherapy for HCC (Tentative) Dr. Thomas Yau (China)
18:35-18:50	5-4 Leukotrienes Derived from Tumor-Infiltrating M2 Macrophages Promote the Progression of Hepatocellular Carcinoma Dr. Takuto Nosaka (Japan)
18:50-19:05	5-5 Multiomics Profiling Identifies the Link between Intra-tumor Steatosis and Immune-exhaustion in Non-viral HCC Dr. Takahiro Kodama (Japan)
19:05-19:20	Discussion Time

19:30-20:30 Evening Seminar (Sponsored by Incyte Biosciences Japan GK)

Chair: Dr. Yukiyasu Okamura (Japan)

New Personalized Approach for Intrahepatic Cholangiocarcinoma Based on Cancer Genomic Diagnosis in Japan
Dr. Naoya Kato (Japan)

Pemigatinib in Cholangiocarcinoma: Targeting FGFR2 Fusions
Dr. Arndt Vogel (Germany)

Day 1: December 17 (Friday) 2021

Room 2

8:00-9:00 Morning Seminar (2) (Sponsored by Otsuka Pharmaceutical Co., Ltd.)

Chair: Dr. Naoya Kato (Japan)

The Usefulness of Tolvaptan as a Treatment of Hepatic Edema among Advanced HCC Patients

Dr. Takamasa Ohki (Japan)

Clinical Symptoms of Liver Diseases: Pathogenesis and Treatment

Dr. Tatsuo Kanda (Japan)

9:05-10:50 Session 6: Surgery and Transplantation

Chairs: Dr. Seth J. Karp (USA)/Dr. Tadatoshi Takayama (Japan)

- 9:05-9:20 6-1 **Placental Stem Cell Transplantation Prevented Disease Development in Ornithine Transcarbamylase Deficiency Model Mice**
Dr. Toshio Miki (Japan)
- 9:20-9:35 6-2 **Minimal Invasive Hepatectomy in the Post-SVR Era**
Dr. Yuji Iimuro (Japan)
- 9:35-9:50 6-3 **Surgery for Perihilar Cholangiocarcinoma: Resection and Transplantation**
Dr. Masayuki Ohtsuka (Japan)
- 9:50-10:05 6-4 **Management of Hepatocellular Carcinoma “Current Therapeutic Options”**
Dr. Washim Jafri (Pakistan)
- 10:05-10:20 6-5 **Proposal of Resectability for Hepatocellular Carcinoma for Future Clinical Trial**
Dr. Etsuro Hatano (Japan)
- 10:20-10:35 6-6 **Hepatoblastoma Management: From Resection To Transplantation**
Dr. Mureo Kasahara (Japan)
- 10:35-10:50 Discussion Time

11:00-12:30 Session 7: HCC in Asia, Epidemiology (1)

Chairs: Dr. Wan Long Chuang (Taiwan)/ Dr. Necati Örmeci (Turkey)/ Dr. Fumio Imazeki (Japan)

- 11:00-11:15 7-1 **HCC in China, Epidemiology (Tentative)**
Dr. Lai Wei (China)
- 11:15-11:30 7-2 **Epidemiological Aspects of HCC Prevention in Asia-Pacific**
Dr. Manoj K Sharma (India)
- 11:30-11:45 7-3 **Changing Epidemiology of Hepatocellular Carcinoma in Taiwan**
Dr. Wan Long Chuang (Taiwan)
- 11:45-12:00 7-4 **The magnified challenge of HCC in Bangladesh in the context of COVID-19 Pandemic**
Dr. Mamun-Al Mahtab (Bangladesh)
- 12:00-12:15 7-5 **HCC Caused by Hepatitis Delta Virus infection in Asia-Pacific**
Dr. Saeed Hamid (Pakistan)
- 12:15-12:30 Discussion Time

12:40-13:40 Luncheon Seminar (2) (Sponsored by Sysmex Co., Ltd.)

Chair: *Dr. Jia-Horng Kao (Taiwan)*

M2BPGi for Liver Fibrosis and Outcome Prediction

Dr. Tung-Hung Su (Taiwan)

14:30-16:00 Session 8: HCC in Asia, Epidemiology (2)

Chairs: *Dr. Hasmik Ghazinyan (Armenia) /Dr. Tatsuya Kanto (Japan)/Dr. Osamu Yokosuka (Japan)*

- 14:30-14:45 8-1 **Epidemiology Hepatocellular Carcinoma (HCC) in Thailand**
Dr. Teerha Piratvisuth (Thailand)
- 14:45-15:00 8-2 **Hepatocellular Carcinoma in Indonesia: Immunology View**
Dr. Rino Gani (Indonesia)
- 15:00-15:15 8-3 **Global Epidemiology & Risk Factors of Hepatocellular Carcinoma**
Dr. Man-Fung Yuen (China)
- 15:15-15:30 8-4 **Epidemiology of HCC in Mongolia**
Dr. Oidov Baatarxuu (Mongolia)
- 15:30-15:45 8-5 **Epidemiology of Viral Hepatitis and HCC in Japan**
Dr. Junko Tanaka (Japan)
- 15:45-16:00 Discussion Time

16:10-17:40 Session 9: Management of HCC and Complications during TKI Treatment

Chairs: *Dr. A. Kadir Dokmeci (Turkey)/Dr. Diana A. Payawal (Philippines)/ Dr. Tetsuo Takehara (Japan)*

- 16:10-16:25 9-1 **HCC Treatment in JRCMC (Japanese Red Cross Medical Center)**
Dr. Hideo Yoshida (Japan)
- 16:25-16:40 9-2 **Management of Adverse Event from the Pharmacological Perspective in Patients with Hepatocellular Carcinoma Using Tyrosine Kinase Inhibitor**
Dr. Hironao Okubo (Japan)
- 16:40-16:55 9-3 **Management of HCC Patient with Portal Vein Thrombosis**
Dr. Shiv Kumar Sarin (India)
- 16:55-17:10 9-4 **Contrast-enhanced US-based Assessment of HCC Hemodynamics Related to Systemic Treatment**
Dr. Hitoshi Maruyama (Japan)
- 17:10-17:25 9-5 **Effective Prevention of TKI-related Vascular Damage induced Adverse Events and Maintenance of Hepatic Function by Dried Bonito Broth and Histidine**
Dr. Kenya Kamimura (Japan)
- 17:25-17:40 Discussion Time

17:50-19:20 Session 10: HCC after SVR

Chairs: *Dr. Shuhei Nishiguchi (Japan) /Dr. Yasuhito Tanaka (Japan)/ Dr. Hiroshi Yatsushashi (Japan)*

- 17:50-18:05 10-1 **Rapid Hepatitis C Virus Clearance by Antivirals Correlates with Immune Status of Infected Patients and Decreased Immune Related Cytokines and Chemokines**
Dr. Reina Sasaki (Japan)

- 18:05-18:20 10-2 **The Clinical and Pathogenic Significance of HCC after Viral Eradication**
Dr. Min-Lung Yu (Taiwan)
- 18:20-18:35 10-3 **Risk of Hepatocellular Carcinoma After Sustained Virological Response in
Hepatitis C Virus Infection**
Dr. Yoichi Hiasa (Japan)
- 18:35-18:50 10-4 **Development of HCC in Treated HBV Patients**
Dr. Jia-Hornng Kao (Taiwan)
- 18:50-19:05 10-5 **Gene Expression Signature Associated with HCC Development after HCV
Eradication**
Dr. Yasuhito Tanaka (Japan)
- 19:05-19:20 Discussion Time

20:00-22:30 APASL Hepatology Webinar “Editor’s Choice” Collaborated with AASLD

Day 1: December 17 (Friday) 2021

Room 3

9:10-10:06 Oral Free Papers (1)

Chairs: Dr. Jun Arai (Japan)/Dr. Takumi Kawaguchi (Japan)/Dr. Naoya Sakamoto (Japan)

- 9:10-9:17 #10046 **Surgical Treatment for Multinodular HCC with Right Hepatic Vein Tumor Thrombosis: A Case Report**
Dr. Giang Nguyen (Viet Nam)
- 9:17-9:24 #10006 **A Case with HCC Successfully Treated with Prednisone for Atezolizumab-Associated Grade 3 Colitis**
Dr. Takahiro Fuji (Japan)
- 9:24-9:31 #10045 **New Research Trends in Onco-carcinogenesis and Nutritional Background Linked with Chronic Inflammation, Iron (Fe) Deposition, and Metabolic Changes**
Dr. Kenichi Furuya (Japan)
- 9:31-9:38 #10061 **Case reports of HCC with IVC and Rt. Atrium Tumor Thrombus and Extension into Left Renal Vein**
Dr. Parimita Barua (India)
- 9:38-9:45 #10005 **Novel Immuno-Oncotherapy against HCC by Targeting MICA**
Dr. Yumi Otoyama (Japan)
- 9:45-9:52 #10066 **Synergistic Nanoassemblies with Enhanced Cancer Chemo-Immunotherapy**
Dr. Xiaowei Shi (China)
- 9:52-9:59 #10012 **Various Uses of Ramucirumab in Real World Practice for Patients with Hepatocellular Carcinoma**
Dr. Naoya Kanogawa (Japan)
- 9:59-10:06 #10049 **Regorafenib and its metabolites could induce NK cell-mediated cytotoxicity in HCC by targeting ADAM9**
Dr. Jun Arai (Japan)

12:30-13:30 Luncheon Seminar (3) (Sponsored by Eisai Co., Ltd./MSD K.K.)

Chair: Dr. Shuntaro Obi (Japan)

LEN-TACE Sequential Therapy as a Therapeutic Strategy for Intermediate-stage Hepatocellular Carcinoma Dr. Yoshiyuki Wada (Japan)

Positioning of Hepatic Arterial Infusion Chemotherapy and Lenvatinib for Advanced Hepatocellular Carcinoma Dr. Tatsuya Yamashita (Japan)

14:30-15:30 Educational Seminar (1) (Sponsored by Miyarisan Pharmaceutical Co., Ltd.)

Chair: Dr. Tadatoshi Takayama (Japan)

Role of Gut Microbiota in Liver Disease and Carcinogenesis

Dr. Nobuhiro Nakamoto (Japan)

15:40-16:50 Oral Free Papers (2)

Chairs: Dr. Yuko Nagaoki (Japan)/Dr. Hidenari Nagai (Japan)

- 15:40-15:47 #10004 **Particle Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis**
Dr. Yoshiro Matsuo (Japan)
- 15:47-15:54 #10024 **Efficacy and Safety of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma in Japan**
Dr. Tadashi Namisaki (Japan)
- 15:54-16:01 #10020 **HCC Surveillance Remains Cost-effective Long after Hepatitis B Surface Antigen Loss: A 12-year Study**
Dr. Terry Cheuk-Fung Yip (Japan)
- 16:01-16:08 #10064 **Hepatocellular Carcinoma Emergence in Armenia: Outcome of Multiple Risk Factors, 2019-2020**
Dr. Hasmik Levon Ghazinyan (Armenia)
- 16:08-16:15 #10058 **Nucleic acid Analog Therapy and Liver Carcinogenesis in Patients with Chronic Hepatitis B**
Dr. Makoto Moriyama (Japan)
- 16:15-16:22 #10029 **Impact of Viral Eradication by DAA on Clinical Outcome after Treatment for HCV Associated HCC**
Dr. Yuko Nagaoki (Japan)
- 16:22-16:29 #10047 **The Comprehensive Prognosis of Chronic Hepatitis C after DAA Therapy for Chronic Hepatitis C**
Dr. Yuki Kanayama (Japan)
- 16:29-16:36 #10023 **Comparison of HBV Reactivation in HCC Patients Who Received TKI and TKI with PD-1 Inhibitor**
Dr. Jin Lei (China)
- 16:36-16:43 #10067 **Occult Hepatitis B Virus Infection in Patients with HCV-Related Hepatocellular Carcinoma**
Dr. Muhammad Abdel-Gawad (Egypt)
- 16:43-16:50 #10069 **Bone Mineral Density in Patients with Non-Alcoholic Fatty Liver Disease**
Dr. Muhammad Abdel-Gawad (Egypt)

Day 2: December 18 (Saturday) 2021

Room 1

8:00-9:00 Morning Seminar (3) (Sponsored by Mitsubishi Tanabe Pharma Corporation)

Chair: Dr. Katsutoshi Tokushige (Japan)

New Findings and Future Prospects, Based on Japanese Patients of Histological Proven NAFLD in Toranomon Hospital Dr. Norio Akuta (Japan)

9:10-10:40 Session 11: Molecular Mechanism of HCC (2)

Chairs: Dr. Shuichi Kaneko (Japan)/Dr. Shinji Tanaka (Japan)/Dr. Lai Wei (China)

- 9:10-9:25 11-1 **The Interaction of Hepatoma Cells and Stromal Cells Via IL-6 Family Cytokines**
Dr. Hayato Hikita (Japan)
- 9:25-9:40 11-2 **Impairment of Homologous Recombination by HBx as the Mechanism for HBV-Related Hepatocarcinogenesis**
Dr. Motoyuki Otsuka (Japan)
- 9:40-9:55 11-3 **Recent Progress in Basic and Clinical Research of Liver Cancer Stem Cells**
Dr. Taro Yamashita (Japan)
- 9:55-10:10 11-4 **Genetic Alterations during Multistep Hepatocarcinogenesis Revealed by Whole Genome Sequencing**
Dr. Haruhiko Takeda (Japan)
- 10:10-10:25 11-5 **Predictive Scores for Hepatocellular Carcinoma Risk Stratification after Achieving SVR Following DAAS**
Dr. Gamal Shiha (Egypt)
- 10:25-10:40 Discussion Time

10:50-12:20 Session 12: HAIC, TACE, RFA, Radiation

Chairs: Dr. Ji Dong-Jia (China)/Dr. Satoshi Mochida (Japan)/Dr. Hitoshi Yoshiji (Japan)

- 10:50-11:05 12-1 **Radiofrequency Ablation for Hepatocellular Carcinoma**
Dr. Ryosuke Tateishi (Japan)
- 11:05-11:20 12-2 **Hepatic Arterial Infusion Chemotherapy (HAIC) in 2021**
Dr. Shuntaro Obi (Japan)
- 11:20-11:35 12-3 **Effective Use of Local Ablation Therapy for the Treatment of Early to Intermediate HCC**
Dr. Kazuhiro Nouso (Japan)
- 11:35-11:50 12-4 **The Key Recommendations by APASL PBC Guidance 2021**
Dr. Ji Dong Jia (China)
- 11:50-12:05 12-5 **Laparoscopic Radiofrequency Ablation in the Era of Non-viral Hepatitis**
Dr. Naoki Morimoto (Japan)
- 12:05-12:20 Discussion Time

12:30-13:30 Luncheon Seminar (4) (Sponsored by AbbVie GK)

Chair: Dr. Masayuki Kurosaki (Japan)

Ultra-FP Treatment could be Affordable Treatment Option for Advanced Stage of HCC

Dr. Yasuteru Kondo (Japan)

Radiofrequency Ablation for Hepatocellular Carcinoma

Dr. Ryosuke Tateishi (Japan)

14:30-16:00 Session 13: Intermediate-stage HCC (TKI, Sorafenib, Regorafenib) (3)

Chairs: Dr. Manoj K Sharma (India)/Dr. Norifumi Kawada (Japan)

14:30-14:45 13-1 **Exploring Tumor Microenvironment in Patients with Advanced Hepatocellular Carcinoma**

Dr. Hiroaki Kanzaki (Japan)

14:45-15:00 13-2 **Management Challenges for Intermediate Stage Hepatocellular Carcinoma (HCC) in the era of Systemic Therapy**

Dr. Cosmas Rinaldi A. Lesmana (Indonesia)

15:00-15:15 13-3 **Impact of Skeletal Muscle Volume in Patients with Intermediate-stage hepatocellular carcinoma (HCC) receiving sorafenib: A comparison with advanced HCC patients**

Dr. Issei Saeki (Japan)

15:15-15:30 13-4 **Mechanisms and Management of Sorafenib Resistance in Hepatocellular Carcinoma**

Dr. Rakhi Maiwall (India)

15:30-15:45 13-5 **Optimal Sequencing of TKI after Atezolizumab and Bevacizumab in HCC**

Dr. Wei-Peng Yong (Singapore)

15:45-16:00 Discussion Time

16:10-17:40 Session 14: Intermediate-stage HCC (5) (Ramucirumab, etc.)

Chairs: Dr. Namiki Izumi (Japan)/Dr. Pei Jer Chen (Taiwan)

16:10-16:25 14-1 **Systemic Therapy for Intermediate-stage Hepatocellular Carcinoma Including Real-world Data of Ramucirumab Treatment as Second or Later Line**

Dr. Yutaka Yasui (Japan)

16:25-16:40 14-2 **Analyses of Intermediate-stage Hepatocellular Carcinoma Patients Receiving TACE Prior to Designing Clinical Trials**

Dr. Keisuke Koroki (Japan)

16:40-16:55 14-3 **Hepatocellular Carcinoma Emergence in Armenia: Outcome of Multiple Risk Factors, January 2019 to March 2020 Nork Clinical Hospital of Infectious Diseases**

Dr. Hasmik Ghazinyan (Armenia)

16:55-17:10 14-4 **Management of Intermediate Hepatocellular Carcinoma - Past, Present and Future**

Dr. George Lau (China)

17:10-17:25 14-5 **Treatment Strategy of Intermediate-stage HCC: LEN-TACE Sequential Therapy**

Dr. Masatoshi Kudo (Japan)

17:25-17:40 Discussion Time

17:40-17:50 Awarding Ceremony

17:50-18:00 Closing Ceremony

Dr. Mitsuhiro Moriyama (President of APASL Oncology 2021)

Day 2: December 18 (Saturday) 2021

Room 2

8:00-9:00 Morning Seminar (4) (Sponsored by Takeda Pharmaceutical Co., Ltd.)

Chair: Dr. Shinichi Takahashi (Japan)

Gastric Cancer Risk with H. Pylori Infection and Gastric Cancer Management in Japan

Dr. Kazunari Murakami (Japan)

9:10-10:40 Session 15: COVID-19 in Japan

Chairs: Dr. Masashi Mizokami (Japan)/Dr. Mitsuhiro Moriyama (Japan)

- 9:10-9:25 15-1 **Diagnosis, Genome Surveillance and Immune Response of COVID-19**
Dr. Yosuke Hirotsu (Japan)
- 9:25-9:40 15-2 **Serum Predictive Factors for Severe Symptoms of COVID-19**
Dr. Masaya Sugiyama (Japan)
- 9:40-9:55 15-3 **Management of Hepatocellular Carcinoma in the Era of COVID-19**
Dr. Shuichiro Shiina (Japan)
- 9:55-10:10 15-4 **Responses to COVID-19 Outbreaks in Healthcare Setting in Japan, January 2020 -
September 2021**
Dr. Takuya Yamagishi (Japan)
- 10:10-10:25 15-5 **COVID-19 in Japan**
Dr. Hiroshi Yotsuyanagi (Japan)
- 10:25-10:40 Discussion Time

10:50-12:20 Session 16: Diagnosis of HCC

Chairs: Dr. Jee-Fu Huang (Taiwan)/Dr. Kiyoshi Hasegawa (Japan)/Dr. Masahiro Ogawa (Japan)

- 10:50-11:05 16-1 **Imaging Evaluation of HCC in the Systemic Treatment Era**
Dr. Takamichi Murakami (Japan)
- 11:05-11:20 16-2 **Tumor Marker Profiles in Patients with Viral and Non-viral Hepatocellular
Carcinoma**
Dr. Hidenori Toyoda (Japan)
- 11:20-11:35 16-3 **Diagnosis of HCC (Tentative)**
Dr. Jin Mo Yang (Korea)
- 11:35-11:50 16-4 **Diagnosis of Hepatocellular Carcinoma by Contrast-enhanced Ultrasound –
Focusing on Early Hepatocellular Carcinoma**
Dr. Hiroko Iijima (Japan)
- 11:50-12:05 16-5 **aMAP Score Prediction of Hepatocellular Carcinoma Development in Patients with
Chronic Liver Disease**
Dr. Takeji Umemura (Japan)
- 12:05-12:20 Discussion Time

12:30-13:30 Luncheon Seminar (5) (Sponsored by Gilead Sciences K.K.)

Chair: Dr. Yoshiyuki Ueno (Japan)

Current Status of HBV Prevalence and Efforts for Eradicating Hepatic Failure by HBV Reactivation in Patients with Cancer Dr. Sachiyo Yoshio (Japan)

Recent Advances in Systemic Therapy for Hepatocellular Carcinoma and Management of Hepatitis B Infection Dr. Kaoru Tsuchiya (Japan)

14:30-16:00 Session 17: Intermediate-stage HCC (TKI, Lenvatinib) (4)

Chairs: Dr. Jin Mo Yang (Korea)/Dr. Kazuaki Chayama (Japan)/Dr. Takuji Torimura (Japan)

- 14:30-14:45 17-1 **Treatment Strategy of Intermediate Stage HCC using Lenvatinib “Lenvatinib TACE Sequential Therapy”**
Dr. Yusuke Kawamura (Japan)
- 14:45-15:00 17-2 **Lenvatinib for Intermediate Stage HCC**
Dr. Yoshinari Asaoka (Japan)
- 15:00-15:15 17-3 **The Dawn of a New Era in Hepatocellular Carcinoma Treatment with Molecular Targeted Therapy and Local Therapy**
Dr. Eishiro Mizukoshi (Japan)
- 15:15-15:30 17-4 **Adjuvant Systemic Therapies in Intermediate HCC**
Dr. Levent Doğanay (Turkey)
- 15:30-15:45 17-5 **Value of Lenvatinib in the Treatment of Intermediate Stage HCC**
Dr. Chun-Jen Liu (Taiwan)
- 15:45-16:00 Discussion Time

16:10-17:40 Session 18: Intermediate-stage HCC (6) (TKI, Lenvatinib)

Chairs: Dr. Sumiko Nagoshi (Japan)/Dr. Yoshiyuki Ueno (Japan)

- 16:10-16:25 18-1 **Contrast-enhanced Ultrasonography for Blood Flow Detection in Hepatocellular Carcinoma During Lenvatinib Therapy**
Dr. Naoki Matsumoto (Japan)
- 16:25-16:40 18-2 **Guidelines in Evolution: Systemic Therapy for Intermediate-stage HCC**
Dr. Chiun Hsu (Taiwan)
- 16:40-16:55 18-3 **Importance of Keeping Balance Between Therapeutic Effects and Adverse Events in Lenvatinib for Hepatocellular Carcinoma~Refinement of Administration Schedule and Combination with Transarterial Therapy~**
Dr. Hideki Iwamoto (Japan)
- 16:55-17:10 18-4 **Role of tumor immunogenicity and tumor-associated macrophages in multi-kinase inhibitor responses for hepatocellular carcinoma**
Dr. Pil Soo Sung (Korea)
- 17:10-17:25 18-5 **The Prediction Model of HBV-HCC During Anti-viral Therapy**
Dr. Hong You (China)
- 17:25-17:40 Discussion Time

Day 2: December 18 (Saturday) 2021

Room 3

8:00-9:00 Morning Seminar (5) (Sponsored by AstraZeneca)

Chair: Dr. Hiroo Imazu (Japan)

Treatment Strategies for Acid Related Disease in Primary Care-Based on Clinical Practice Guidelines for GERD 2021 Dr. Akihito Nagahara (Japan)

9:10-10:34 Oral Free Papers (3)

Chairs: Dr. Shinya Maekawa (Japan)/Dr. Masahito Shimizu (Japan)/Dr. Katsutoshi Tokushige (Japan)

9:10-9:17 #10008 **Contribution of dMMR to Accumulation of Somatic Mutations at Different Stages of HCC Development**

Dr. Masayuki Ueno (Japan)

9:17-9:24 #10033 **Genetic Discrimination between Multicentric Occurrence and Intrahepatic Metastasis in Multifocal HCC**

Dr. Yuji Iimuro (Japan)

9:24-9:31 #10015 **An Assistive Computational Tool for Defining the Segmental Anatomy of the Liver**

Dr. Harvey Ho (New Zealand)

9:31-9:38 #10035 **The Protective Role of DNA Methyltransferase 3B Against Inflammatory Hepatocarcinogenesis**

Dr. Eriko Iguchi (Japan)

9:38-9:45 #10060 **Utility of AFP, AFP-L3, and PIVKA-II for Hepatocellular Carcinoma Surveillance**

Dr. Supot Nimanong (Thailand)

9:45-9:52 #10062 **Natural Killer Cells Putative Role in Patients with HCV-Related Hepatocellular Carcinoma**

Dr. Mohamed Abdel-Samiee (Egypt)

9:52-9:59 #10076 **Let-7a and Let-7i as Biomarkers for CHC Patients with HCC Risk after Anti-viral Treatment**

Dr. Ming-Lung Yu (Taiwan)

9:59-10:06 #10009 **Post-treatment Cell-free DNA as a Predictive Biomarker in Systemic Therapy for HCC**

Dr. Takuma Nakatsuka (Japan)

10:06-10:13 #10026 **The Combination of ALBI and PT Predict Liver Dysfunction after TACE for HCC within Up-to-7 Criteria**

Dr. Hiroaki Takaya (Japan)

10:13-10:20 #10063 **MicroRNA Gene Polymorphisms and Development of Hepatocellular Carcinoma in Egyptian Patients**

Dr. Mohamed Abdel-Samiee (Egypt)

10:20-10:27 #10079 **Analysis of Sarcopenia in Patients with BCLC Stage B HCC who Received Atezolizumab Plus Bevacizumab**

Dr. Hiroaki Matsumoto (Japan)

10:27-10:34 #10080 **The Simple Product of Albumin and Platelets Indicates the Stage of Liver Fibrosis and Prognosis**

Dr. Koji Fujita (Japan)

11:00-12:00 Educational Seminar (2) (Sponsored by AbbVie GK)

Chair: Dr. Junko Tanaka (Japan)

SVR & HCV-related HCC

Dr. Yoshinari Asaoka (Japan)

HCV Eradication in the SDGs Era

Dr. Hironao Okubo (Japan)